Ramp Up Your AAV Production With The Xcite® AAV Platform Technology

With the AAV market gaining momentum, gene therapy developers are under increasing pressure to advance their AAV-based therapeutics for clinical trials quickly, while managing the risks and the time-consuming steps of gene therapy drug development. Leveraging Lonza expertise and the same tools and technologies implemented for our platform process, you can balance risk and speed, while maintaining high AAV productivity. Xcite™ AAV platform technology is established based on our proprietary suspension HEK293 cell line and plasmid vectors, proven to enhance AAV production. These materials are now available for use in your own laboratory.